Related Experiment Video
Updated: Jun 17, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Mycophenolate sodium for immunosuppressive treatment in uveitis
Christoph M E Deuter1, Deshka Doycheva, Nicole Stuebiger
1Centre for Ophthalmology, University of Tübingen, Tübingen, Germany. christoph.deuter@med.uni-tuebingen.de
Ocular Immunology and Inflammation
|December 17, 2009
Summary
Mycophenolate sodium (MPS) effectively controlled intraocular inflammation in most uveitis patients. This immunosuppressive drug demonstrated good tolerability and improved visual acuity, offering a promising treatment option.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Uveitis is a significant cause of vision loss.
- Systemic corticosteroids and other immunomodulators are common treatments.
- Alternative immunosuppressive therapies are needed for refractory cases.
Purpose of the Study:
- To evaluate the efficacy of mycophenolate sodium (MPS) in managing uveitis.
- To assess the tolerability and safety profile of MPS in uveitis patients.
Main Methods:
- Retrospective analysis of 35 uveitis patients treated with MPS (Myfortic).
- MPS dosage: 720 mg twice daily for at least 3 months.
- Data collected on inflammation control, visual acuity, and adverse events.
Main Results:
- MPS controlled intraocular inflammation in 85.7% of patients.
- Visual acuity stabilization or improvement occurred in 92.3% of eyes.
- MPS was well-tolerated by 97.1% of patients.
Conclusions:
- Mycophenolate sodium is an effective immunosuppressive treatment for various forms of uveitis.
- MPS demonstrates a favorable tolerability profile in this patient cohort.
- MPS offers a valuable therapeutic option for uveitis management.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...